Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

BridgeBio: 3 Key Takeaways for Long-Term Investors

Key PointsAttruby net product revenue grew 134% year over year to $253.2 million.

Three key takeaways emerged from BridgeBio's Q3 2026 earnings call on October 29, 2026. First, net product revenue for Attruby reached $253.2 million, marking a 134% year-over-year increase. Second, rare disease therapies show commercial momentum, with an addressable market expanding beyond $8 billion in peak annual sales. Third, the company anticipates FDA decisions on two potential treatments for genetic disorders by November 27, 2026, in line with a November 27 PDUFA action date.

These approvals, alongside three commercial launches in the next seven months, signal an operational shift and potential margin expansion toward corporate breakeven.

Rewritten by urgent.news; may contain errors — check the original.

Sources: fool.com · nasdaq.com

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at nasdaq.com →

Report a problem with this story

More in Finance & Markets

More from Sunday 22 November →